CERO THERAPEUTICS HOLDINGS, INC. (CERO): Nasdaq/NYSE listing notice — Nasdaq Listing Council affirms delisting of CERo Therapeutics securities

CERO THERAPEUTICS HOLDINGS, INC.

On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.
Delisting and trading suspension originally effective Oct 31, 2025; the Council's affirmance makes the delisting final.
Common stock ticker CERO and warrants ticker CEROW will no longer trade on Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding other.

Exchange: nasdaq
Notice: delisting notice

Exact text from the filing

January 29, 2026, after considering the written record in this matter, the Council issued its decision affirming the Panel’s decision to delist the Company’s securities from Nasdaq. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 3, 2026 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-011587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.